Open access
Aug 2026
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.
Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications, and these findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population.
Konstantinos D. Rizas, K. Mourouzis, D. Rath et al.
· Nature Medicine · 3 citations